Drug Approval | April 18, 2022
Amneal achieves second U.S. biosimilars approval with Alymsys
Marks the second of three biosimilars Amneal expects to receive U.S. approval for in 2022
Marks the second of three biosimilars Amneal expects to receive U.S. approval for in 2022
Momelotinib complements GSK’s existing expertise in haematology, with Sierra Oncology anticipating US regulatory submission in Q2 this year and EU submission in the second half of 2022
The initial courses of Lap. Hernia Masterclass will encompass commonly performed hernia procedures
Dr. Mansukh Mandaviya launches a quarterly report on AB-HWCs, Guidelines on Human resources for health, Public Health Management Cadre’ Guidance for implementation and Indian Public Health Standards Guidelines; interacts with healthcare workers from across the country
Ocular hypertension affects over 5% of all adults; the eye does not properly drain fluid, causing eye pressure to build up
The US $600 million acquisition will see Juniper Biologics offer the world's first cell-mediated gene therapy to an estimated 300 million patients in Asia Pacific, Middle East and Africa
The total investment is in the region of Rs 200 crore
An RMAT confers eligibility for accelerated approval and priority review of biologics licensing applications (BLA)
Turn has developed a novel cell rejuvenating platform with significant potential for application in an array of age-related diseases
Shoreline has developed a proprietary methodology to create differentiated iNK cells for large-scale, "off-the-shelf" production
Subscribe To Our Newsletter & Stay Updated
